The present invention provides turn-ON dioxetane-based chemiluminescence probes based on the Schapp's adamantylidene-dioxetane probe, which emit light in the near-infrared (NIR) region and are therefore useful for in vivo imaging, as well as compositions and uses thereof.

The invention provides efficient cyclization processes of hydroxyalkenoic acids and products produced therefrom. The following reactions are claimed: Formula (I), (II), (V) and (VI).

##STR00001##

The invention provides efficient cyclization processes of hydroxyalkenoic acids and products produced therefrom. The following reactions are claimed: Formula (I), (II), (V) and (VI).

##STR00001##

The present invention relates to compounds of formula (I) and to pharmaceutical compositions containing them:

##STR00001##

wherein meanings of the substituents are indicated in the description.

Such compounds for use in the treatment of cancer and other diseases related to altered angiogenesis, such as arthritic pathology, diabetic retinopathy, psoriasis and chronic inflammatory disease, are also within the scope of the present invention.

An object of the present invention is to develop a therapeutic agent for an inflammatory disease such as an inflammatory bowel disease or NASH, which therapeutic agent shows less side effects and high effectiveness. The present invention provides a compound represented by Formula (I) or a salt thereof; and a Pin1 inhibitor, a pharmaceutical composition, a therapeutic agent or a prophylactic agent for an inflammatory disease, and a therapeutic agent or a prophylactic agent for colon cancer, containing the compound.

##STR00001##

An object of the present invention is to develop a therapeutic agent for an inflammatory disease such as an inflammatory bowel disease or NASH, which therapeutic agent shows less side effects and high effectiveness. The present invention provides a compound represented by Formula (I) or a salt thereof; and a Pin1 inhibitor, a pharmaceutical composition, a therapeutic agent or a prophylactic agent for an inflammatory disease, and a therapeutic agent or a prophylactic agent for colon cancer, containing the compound.

##STR00001##

A low sulfur diesel blockage inhibitor as shown in formula (I), a preparation method therefor, and use thereof are provided. In formula (I), x and y are each an integer between 0 and 4; m and n are each selected from H, a C1-C6 linear or branched alkyl group, or a C3-C6 cycloalkyl group. By using a vegetable oil as a raw material, a modified vegetable oil fatty acid is first obtained, and then a polar group of an unsaturated dialdehyde with a certain chain length is introduced into a molecular chain of the modified vegetable oil fatty acid. ##STR00001##

A low sulfur diesel blockage inhibitor as shown in formula (I), a preparation method therefor, and use thereof are provided. In formula (I), x and y are each an integer between 0 and 4; m and n are each selected from H, a C1-C6 linear or branched alkyl group, or a C3-C6 cycloalkyl group. By using a vegetable oil as a raw material, a modified vegetable oil fatty acid is first obtained, and then a polar group of an unsaturated dialdehyde with a certain chain length is introduced into a molecular chain of the modified vegetable oil fatty acid. ##STR00001##

The invention provides compounds which directly inhibit IRE-1 activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies.

The invention provides compounds which directly inhibit IRE-1 activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies.